Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model

Area of Science:

• Pharmacology
• Immunology
• Respiratory Medicine

Background:

• Chronic use of beta(2)-adrenoceptor (beta(2)-AR) agonists in asthma correlates with decreased disease control and increased mortality risk.
• Beta(2)-AR inverse agonists have shown potential in attenuating asthma phenotypes in preclinical models.

Purpose of the Study:

• To elucidate the mechanism by which beta(2)-AR inverse agonists exert their therapeutic effects in asthma.
• To investigate the role of beta(2)-AR signaling in the development of cardinal asthma features.

Main Methods:

• Comparison of asthma phenotypes in beta(2)-AR-null mice and wild-type mice following allergen challenge.
• Administration of beta(2)-AR inverse agonists and a non-inverse agonist beta-blocker (alprenolol) in a murine asthma model.

Main Results:

• Beta(2)-AR-null mice exhibited reduced mucous metaplasia, airway hyperresponsiveness (AHR), and pulmonary inflammatory cells, mirroring effects of beta(2)-AR inverse agonists.
• The observed therapeutic effects of beta(2)-AR inverse agonists were attributed to the inhibition of beta(2)-AR signaling, not novel pathway activation.
• Alprenolol treatment did not attenuate the asthma phenotype, indicating that signaling by unoccupied beta(2)-ARs contributes to the asthma phenotype.

Conclusions:

• Beta(2)-AR signaling is essential for the full manifestation of mucous metaplasia, AHR, and inflammatory cell infiltration in the lungs in a murine asthma model.
• The findings suggest that targeting beta(2)-AR signaling, potentially through inverse agonists, could be a viable therapeutic strategy for managing asthma.